US5254715A - Aminosulfonyl carbamates - Google Patents
Aminosulfonyl carbamates Download PDFInfo
- Publication number
- US5254715A US5254715A US07/747,031 US74703191A US5254715A US 5254715 A US5254715 A US 5254715A US 74703191 A US74703191 A US 74703191A US 5254715 A US5254715 A US 5254715A
- Authority
- US
- United States
- Prior art keywords
- bis
- phenyl
- carbamate
- sulfonyl
- methylethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C307/04—Diamides of sulfuric acids
- C07C307/06—Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C307/04—Diamides of sulfuric acids
- C07C307/08—Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C307/04—Diamides of sulfuric acids
- C07C307/10—Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Definitions
- This invention relates to chemical compounds having pharmacological activity, to pharmaceutical compositions which include these compounds, and to a pharmaceutical method of treatment. More particularly, this invention concerns certain aminosulfonyl carbamates which inhibit the enzyme acyl-coenzyme A:cholesterol acyltransferase (ACAT), pharmaceutical compositions containing these compounds, and a method of treating hypercholesterolemia and atherosclerosis.
- ACAT acyl-coenzyme A:cholesterol acyltransferase
- LDL cholesterol low density lipoprotein cholesterol
- HDL cholesterol high density lipoprotein cholesterol
- agents which are more selective in their action that is, agents which are effective in elevating the blood serum levels of HDL cholesterol and/or lowering the levels of LDL cholesterol. While such agents are effective in moderating the levels of serum cholesterol, they have little or no effect on controlling the initial absorption of dietary cholesterol in the body through the intestinal wall.
- dietary cholesterol is absorbed as free cholesterol which must be esterified by the action of the enzyme acyl-CoA:cholesterol acyltransferase (ACAT) before it can be packaged into the chylomicrons which are then released into the blood stream.
- ACAT acyl-CoA:cholesterol acyltransferase
- German patent 940,292 dated Mar. 15, 1956 to Farbwerke Hoechst, Ag describes the folloiwng compounds which are said to be useful as textile assistants, pharmaceuticals and pesticides. No specific pharmaceutical utility is described.
- the present invention provides compounds of the following general Formula I, methods of using said compounds, pharmaceutical compositions and process for preparing the compounds of Formula I ##STR13## wherein X is sulfur or oxygen; wherein R is hydrogen, a straight or branched alkyl having from 1 to 8 carbon atoms, or benzyl;
- alkyl having from one to six carbon atoms and which is straight or branched
- alkoxy having from one to six carbon atoms and which is straight or branched
- alkyl has from one to four carbon atoms and which is straight or branched
- alkyl having from one to six carbon atoms and which is straight or branched
- alkoxy having from one to six carbon atoms and which is straight or branched
- alkyl has from one to four carbon atoms and is straight or branched
- R 6 and R 7 are independently selected from hydrogen or alkyl having for one to six carbon atoms, or when R 6 is hydrogen, R 7 can be selected from the groups defined for R 8 ; and R 8 is phenyl or phenyl substituted with from one to three substituents selected from straight or branched alkyl having from one to six carbon atoms, straight or branched alkoxy having from one to six carbon atoms, phenoxy, hydroxy, fluorine, chlorine, bromine, nitro, trifluoromethyl, --COOH, COOalkyl wherein alkyl has from one to four carbon atoms and is straight or branched, or --(CH 2 ) p NR 4 R 5 wherein p, R 4 and R 5 have the meanings defined above;
- alkyl having from one to six carbon atoms and which is straight or branched
- alkoxy having from one to six carbon atoms and which is straight or branched
- NR 1 R 2 taken together form a monocyclic heterocyclic group selected from pyrrolidino, piperidino, morpholino, or piperazino, each of which is unsubstituted or substituted with one substituent selected from phenyl, straight or branched alkyl having from one to six carbon atoms; and pharmaceutically acceptable salts thereof; with the provisos:
- R 7 is hydrogen or alkyl having from one to six carbon atoms; (ii) at least one of R 1 , R 2 , and R 3 is phenyl or substituted phenyl;
- R 1 when R 1 is phenyl disubstituted on the 2,6-positions or trisubstituted on the 2,4,6-positions with alkyl having from one to four carbon atoms, or when R 1 is phenyl disubstituted on the 2,6-positions with methoxy, neither of R 2 or R 3 is phenyl;
- the present invention also provides pharmaceutical compositions containing compounds of the following general Formula II and the method of treating hypercholesterolemia and atherosclerosis using the compounds of the following Formula II: ##STR19## wherein X is sulfur or oxygen; wherein R is hydrogen, a straight or branched alkyl having from 1 to 8 carbon atoms, or benzyl;
- alkyl has from one to four carbon atoms and which is straight or branched
- alkyl having from one to six carbon atoms and which is straight or branched
- alkoxy having from one to six carbon atoms and which is straight or branched
- alkyl has from one to four carbon atoms and is straight or branched
- R 6 and R 7 are independently selected from hydrogen or alkyl having for one to six carbon atoms, or when R 6 is hydrogen, R 7 can be selected from the groups defined for R 8 ; and R 8 is phenyl or phenyl substituted with from one to three substituents selected from straight or branched alkyl having from one to six carbon atoms, straight or branched alkoxy having from one to six carbon atoms, phenoxy, hydroxy, fluorine, chlorine, bromine, nitro, trifluoromethyl, --COOH, COOalkyl wherein alkyl has from one to four carbon atoms and is straight or branched, or --(CH 2 ) p NR 4 R 5 wherein p, R 4 and R 5 have the meanings defined above;
- alkyl having from one to six carbon atoms and which is straight or branched
- alkoxy having from one to six carbon atoms and which is straight or branched
- NR 1 R 2 taken together form a monocycl heterocyclic group selected from pyrrolidino, piperidino, morpholino, or piperazino, each of which is unsubstituted or substituted with one substituent selected from phenyl, straight or branched alkyl having from one to six carbon atoms; and pharmaceutically acceptable salts thereof; with the provisos:
- R 7 is hydrogen or alkyl having from one to six carbon atoms; (ii) at least one of R 1 , R 2 , and R 3 is phenyl or substituted phenyl;
- the compounds of the present invention provide a novel class of aminosulfonyl carbamates which are ACAT inhibitors rendering them useful in treating hypercholesterolemia and atherosclerosis.
- Illustrative examples of straight or branched saturated hydrocarbon chains having from 1 to 20 carbon atoms include methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, tert-butyl, n-pentyl, isopentyl, n-hexyl, n-heptyl, n-octyl, n-undecyl, n-dodecyl, n-hexadecyl, 2,2-dimethyldodecyl, 2-tetradecyl, and n-octadecyl groups.
- Illustrative examples of straight or branched hydrocarbon chains having from 1 to 20 carbon atoms and having from 1 to 3 double bonds include ethenyl, 2-propenyl, 2-butenyl, 3-pentenyl, 2-octenyl, 5-nonenyl, 4-undecenyl, 5-heptadecenyl, 3-octadecenyl, 9-octadecenyl, 2,2-dimethyl-11-eicosenyl, 9,12-octadecadienyl, and hexadecenyl.
- Straight or branched alkoxy groups having one to six carbon atoms include, for example, methoxy, ethoxy, n-propoxy, t-butoxy, and pentyloxy.
- Straight or branched alkyl groups having from one to six carbon atoms include, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, n-pentyl, n-hexyl, and tert-butyl.
- a 5- or 6-membered monocyclic or fused bicyclic heterocycle is a monocyclic or fused bicyclic aromatic ring containing at least one to four heteroatoms in at least one ring, such as nitrogen, oxygen, or sulfur or a combination thereof.
- Such a heterocyclic group includes, for example, thienyl, benzothienyl, furanyl, benzofuranyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, pyrazolyl, isothiazolyl, thiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, imidazolyl, benzothiazolyl, indolyl, quinolinyl, isoquinolinyl, or N-oxides of heterocycle containing a nitrogen atom.
- such a heterocycle may be a 2- or 3-thienyl; 2- or 3-furanyl; 2-, or 3-, or 4-pyridyl or 2-, or 3-, or 4-pyridyl-N-oxide; 2-, 4-, or 5-pyrimidinyl; 3- or 4-pyridazinyl; 2-pyrazinyl; 2-pyrazinyl-N-oxide; 2- or 3-pyrrolyl; 3-, 4-, or 5-pyrazolyl; 2-, 4-, or 5-thiazolyl; 3-, 4-, or 5-isoxazolyl; 2-, 4-, or 5-oxazolyl; 3-, 4-, or 5-isothiazolyl; 5-tetrazolyl; 3- or 5-(1,2,4,-)triazolyl; 4- or 5-(1,2,3-)triazolyl; 2-, 4-, or 5-imidazolyl; 2-, 3-, 4-, 5-, 6-, or 7-indolyl; 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolinyl;
- Preferred compounds of general Formulas I and II are those wherein one of R 1 , R 2 , and R 3 is phenyl disubstituted in the 2,6-positions. More preferably R 1 and R 2 are 2,6-disubstituted phenyl and R 3 is hydrogen.
- Compounds wherein R 1 is 2,6-disubstituted phenyl and R 2 and R 3 are a straight or branched hydrocarbon chain having from 1 to 20 carbon atoms, and more preferably, 6 to 18 carbon atoms, and which is saturated or contains from 1 to 3 double bonds are also preferred.
- the base salts may be generated from compounds of Formula I and Formula II by reaction of the latter with one equivalent of a suitable nontoxic, pharmaceutically acceptable base followed by evaporation of the solvent employed for the reaction and recrystallization of the salt, if required.
- the compounds of Formula I may be recovered from the base salt by reaction of the salt with an aqueous solution of a suitable acid such as hydrobromic, hydrochloric, or acetic acid, or by reaction with a suitable alkylating agent such as an alkyl halide, e.g., methyl iodide or benzyl bromide.
- Suitable bases for forming base salts of the compounds of this invention include amines such as triethylamine or dibutylamine, or alkali metal bases and alkaline earth metal bases.
- Preferred alkali metal hydroxides and alkaline earth metal hydroxides as salt formers are the hydroxides of lithium, sodium, potassium, or calcium.
- the class of bases suitable for the formation of nontoxic, pharmaceutically acceptable salts is well known to practitioners of the pharmaceutical formulation arts. See, for example, Stephen N. Berge, et al, J Pharm Sciences 66:1-19 (1977).
- Suitable acids for forming acid salts of the compounds of Formulas I and II containing a basic group include, but are not necessarily limited to acetic, benzoic, benzenesulfonic, tartaric, hydrobromic, hydrochloric, citric, fumaric, gluconic, glucuronic, glutamic, lactic, malic, maleic, methanesulfonic, pamoic, salicylic, stearic, succinic, sulfuric, and tartaric acids.
- the acid addition salts are formed by procedures well known in the art.
- Certain compounds of the present invention may also exist in different stereoisomeric forms by virtue of the presence of asymmetric centers in the compound.
- the present invention contemplates all stereoisomers may be obtained, if desired, by methods known in the art as, for example, the separation of stereoisomers in chiral chromatographic columns.
- the compounds of this invention may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like.
- the solvated forms are considered equivalent to the unsolvated forms for the purposes of this invention.
- the compounds of the present invention are potent inhibitors of the enzyme acyl-CoA: cholesterol acyltransferase (ACAT), and are thus effective in inhibiting the esterification and transport of cholesterol across the intestinal cell wall.
- ACAT cholesterol acyltransferase
- the compounds of the present invention are thus useful in pharmaceutical formulations for the treatment of hypercholesterolemia or atherosclerosis.
- test assesses the ability of a test compound to inhibit the acylation of cholesterol by oleic acid by measuring the amount of radiolabeled cholesterol oleate formed from radiolabeled oleic acid in a tissue preparation containing rabbit intestinal microsomes.
- IC50 values i. e., the concentration of test compound required to inhibit the activity of the enzyme by 50%.
- APCC In one in vivo screen designated APCC, male Sprague-Dawley rats (200 to 225 g) were randomly divided into treatment groups and dosed at 4 PM with either vehicle (CMC/Tween) or suspensions of compounds in vehicle. The normal chow diet was then replaced with a high fat, high cholesterol diet with 0.5% cholic acid. The rats consumed this diet ad libitum during the night and were sacrificed at 8 AM to obtain blood samples for cholesterol analysis using standard procedures. Statistical differences between mean cholesterol values for the same vehicle were determined using analysis of variance followed by Fisher's least significant test. The results of this trial for representative compounds of the present invention appear in Table 2. The compounds were dosed at 30 mg/kg unless otherwise noted.
- the compounds of Formula I or pharmaceutically acceptable salts thereof are administered to the patient at dosage levels of from 250 to 3000 mg per day. For a normal human adult of approximately 70 kg of body weight, this translates into a dosage of from 5 to 40 mg/kg of body weight per day.
- the specific dosages employed, however, may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the activity of the compound being employed. The determination of optimum dosages for a particular situation is within the skill of the art.
- inert, pharmaceutically acceptable carriers can be either solid or liquid.
- Solid form preparations include powders, tablets, dispersible granules, capsules, and cachets.
- a solid carrier can be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or tablet disintegrating agents; it can also be an encapsulating material.
- the carrier is a finely divided solid which is in a mixture with the finely divided active component.
- the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
- Powders and tablets preferably contain between about 5% to about 70% by weight of the active ingredient.
- Suitable carriers are magnesium dicarbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low-melting wax, cocoa butter, and the like.
- preparation is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component (with or without carriers) is surrounded by a carrier, which is thus in association with it. In a similar manner cachets are also included.
- Tablets, powders, cachets, and capsules can be used as solid dosage forms suitable for oral administration.
- Liquid form preparations include solutions, suspensions, or emulsions suitable for oral administration.
- Aqueous solutions for oral administration can be prepared by dissolving the active compound in water and adding suitable flavorants, coloring agents, stabilizers, and thickening agents as desired.
- Aqueous suspensions for oral use can be made by dispersing the finely divided active component in water together with a viscous material such as natural or synthetic gums, resins, methyl cellulose, sodium carboxymethylcellulose, and other suspending agents known to the pharmaceutical formulation art.
- the pharmaceutical preparation is in unit dosage form.
- the preparation is divided into unit doses containing appropriate quantities of the active component.
- the unit dosage form can be a packaged preparation containing discrete quantities of the preparation, for example, packeted tablets, capsules, and powders in vials or ampoules.
- the unit dosage form can also be a capsule, cachet, or tablet itself, or it can be the appropriate number of these packaged forms.
- An alcohol or thiol of the formula R 1 XH is reacted with chlorosulfonyl isocyanate in an inert organic solvent such as THF, Et 2 O, CH 2 Cl 2 at room temperature or preferably colder ( ⁇ 0° C.).
- the resulting chlorosulfonyl (thio) carbamate may precipitate out of solution or it can be triturated with a non polar solvent such as hexanes.
- the chlorosulfonyl (thio) carbamate can be isolated or it can be used as is and reacted with an amine of the formula NHR 2 R 3 in an inert organic solvent such as those mentioned above at ambient temperature in the presence of an acid scavenger such as triethylamine.
- the oxysulfonyl (thio) carbamate thus formed can be converted to its base salt by reacting with an appropriate metal or amine base.
- the base salt can then be reacted with an appropriate alkylating agent such as methyl iodide or benzyl bromide.
- the alcohols R 1 OH, thiols, R 1 SH, and amines NHR 2 R 3 used in preparing the compounds of this invention are known in the art or are prepared by procedures generally known in the art.
- Example 44 through 49 teach the preparation of intermediates useful in preparing final products of the present invention.
- 1,8-Diazabicyclo[5.4.0]undec-7-ene (1.0 mL, 6.7 mmol) was added in one portion to a solution of 2,6-bis(1,1-dimethylethyl)phenyl[[(diphenylmethyl)amino]sulfonyl]carbamate (3.0 g, 6.1 mmol) and methyl iodide (0.95 g, 6.7 mmol) in 50 mL acetonitrile at room temperature and the resulting mixture was stirred for 16 hours. Partitioned between 1N HCl and ethyl acetate. Dried the organic layer over MgSO 4 , filtered, and evaporated to give an orange oil. Chromatography on silica gel gave the title compound, mp 175°-178° C.
Abstract
A compound of the following general formula which is useful in treating hypocholesterolemia and atherosclerosis: ##STR1## wherein X is oxygen or sulfur; R is hydrogen, alkyl having from 1 to 8 carbon atoms, or benzyl; R1 is phenyl, substituted phenyl, naphthyl, substituted naphthyl, an aralkyl group, a heterocyclic group, or a hydrocarbon chain of from 1 to 20 carbon atoms which is saturated or contains 1 to 3 double bonds and each of R2 and R3 is selected from hydrogen, provided both are not hydrogen, an aralkyl group, a hydrocarbon chain of from 1 to 20 carbon atoms which is saturated or contains 1 to 3 double bonds, an w-substituted alkylC1-6, a heterocyclic group, phenyl, substituted phenyl or NR2 R3 taken together form a monocyclic heterocyclic group.
Description
This application is a continuation-in-part of copending application Ser. No. 07/610,487, filed Nov. 7, 1990, now abandoned.
This invention relates to chemical compounds having pharmacological activity, to pharmaceutical compositions which include these compounds, and to a pharmaceutical method of treatment. More particularly, this invention concerns certain aminosulfonyl carbamates which inhibit the enzyme acyl-coenzyme A:cholesterol acyltransferase (ACAT), pharmaceutical compositions containing these compounds, and a method of treating hypercholesterolemia and atherosclerosis.
In recent years the role which elevated blood plasma levels of cholesterol plays in pathological conditions in man has received much attention. Deposits of cholesterol in the vascular system have been indicated as causative of a variety of pathological conditions including coronary heart disease.
Initially, studies of this problem were directed toward finding therapeutic agents which would be effective in lowering total serum cholesterol levels. It is now known that cholesterol is transported in the blood in the form of complex particles consisting of a core of cholesteryl esters plus triglycerides and an exterior consisting primarily of phospholipids and a variety of types of protein which are recognized by specific receptors. For example, cholesterol is carried to the sites of deposit in blood vessels in the form of low density lipoprotein cholesterol (LDL cholesterol) and away from such sites of deposit by high density lipoprotein cholesterol (HDL cholesterol).
Following these discoveries, the search for therapeutic agents which are more selective in their action: that is, agents which are effective in elevating the blood serum levels of HDL cholesterol and/or lowering the levels of LDL cholesterol. While such agents are effective in moderating the levels of serum cholesterol, they have little or no effect on controlling the initial absorption of dietary cholesterol in the body through the intestinal wall.
In intestinal mucosal cells, dietary cholesterol is absorbed as free cholesterol which must be esterified by the action of the enzyme acyl-CoA:cholesterol acyltransferase (ACAT) before it can be packaged into the chylomicrons which are then released into the blood stream. Thus, therapeutic agents which effectively inhibit the action of ACAT prevent the intestinal absorption of dietary cholesterol into the blood stream or the reabsorption of cholesterol which has been previously released into the intestine through the body's own regulatory action.
Phosphorus and Sulfur 19(2), 167-172 (1984) describes the following compounds as fungicides and bactericides. ##STR2## Ar= 2,6-dimethylphenyl
2,6-dimethoxyphenyl
2,6-diisopropylmethyl
2-methyl-6-isopropylphenyl
2,6-di-tert-butylphenyl
2,6-di-tert-butyl-4-methylphenyl
2,4,6-tri-tert-butylphenyl
German patent 940,292 dated Mar. 15, 1956 to Farbwerke Hoechst, Ag describes the folloiwng compounds which are said to be useful as textile assistants, pharmaceuticals and pesticides. No specific pharmaceutical utility is described.
______________________________________
##STR3##
R' R"
______________________________________
C.sub.12 H.sub.25 H
C.sub.2 H.sub.5 4-(OC.sub.2 H.sub.5)Ph
C.sub.2 H.sub.5 Ph
C.sub.2 H.sub.5
##STR4##
C.sub.18 H.sub.35
##STR5##
CH.sub.3 Ph
C.sub.2 H.sub.5 C.sub.6 H.sub.11
ClCH.sub.2 CH.sub.2
Ph
ClCH.sub.2 CH.sub.2
4-CH.sub.3 Ph
C.sub.3 H.sub.7 C.sub.3 H.sub.7
i-C.sub.3 H.sub.7 C.sub.6 H.sub.11
CH.sub.2 CHCH.sub.2
Ph
CH.sub.2 CHCH.sub.2
CH.sub.2 CHCH.sub.2
C.sub.4 H.sub.9 Ph
C.sub.4 H.sub.9 C.sub.6 H.sub.11
C.sub.4 H.sub.9 H
(Et).sub.2 CHCH.sub.2
H
(C.sub.4 H.sub.9)(C.sub.2 H.sub.5)CHCH.sub.2
H
C.sub.6 H.sub.11 Ph
PhCH.sub.2 C.sub.3 H.sub.7
Ph H
4-ClPh CH.sub.2 CHCH.sub.2
CH.sub.3 OCH.sub.2
CH.sub.2 CHCH.sub.2
PhCH.sub.2
##STR6##
C.sub.12 H.sub.25
##STR7##
C.sub.18 H.sub.35 CH.sub.2 CH.sub.2 NEt.sub.2
______________________________________
Chem. Ber. 96,56-67 (1963) describes compounds of the following formula. No utility for these compounds is disclosed.
______________________________________
##STR8##
R R' R"
______________________________________
CH.sub.3 H Ph
CH.sub.3 H C.sub.6 H.sub.11
C.sub.2 H.sub.5 H C.sub.6 H.sub.11
C.sub.2 H.sub.5 H Ph
C.sub.2 H.sub.5 H
##STR9##
C.sub.2 H.sub.5 H 4-(COC.sub.2 H.sub.5)Ph
ClCH.sub.2 CH.sub.2
CH.sub.3 CH.sub.3
ClCH.sub.2 CH.sub.2
H 4-CH.sub.3 Ph
-n-C.sub.3 H.sub.7
H - n-C.sub.3 H.sub.7
.sub.- i-C.sub.3 H.sub.7
H Ph
C.sub.12 H.sub.25
CH.sub.3 CH.sub.3
C.sub.18 H.sub.37
CH.sub.3 CH.sub.3
CH.sub.2 CHCH.sub.2
H CH.sub.2 CHCH.sub.2
CH.sub.2 CHCH.sub.2
H Ph
C.sub.6 H.sub.11 CH.sub.3 CH.sub.3
C.sub.6 H.sub.11 H Ph
Ph CH.sub.3 CH.sub.3
Ph H Ph
Ph H - n-C.sub.3 H.sub.7
Ph H - n-C.sub.4 H.sub.9
Ph H
##STR10##
______________________________________
J. Med. Chem. 8,781-784 (1965) describes the following compounds which are useful as hypoglycemic agents. ##STR11##
Tetrahedron Letters 24, (30) 3091-3094 (1983) describes the following compounds. No use is described for these compounds.
______________________________________
##STR12##
X R
______________________________________
Cl Ph
Br Ph
Cl CH.sub.2 Ph
Cl (C.sub.2 H.sub.5).sub.2
Cl C.sub.6 H.sub.11
Cl (CH.sub.2).sub.4 CH.sub.3
______________________________________
The present invention provides compounds of the following general Formula I, methods of using said compounds, pharmaceutical compositions and process for preparing the compounds of Formula I ##STR13## wherein X is sulfur or oxygen; wherein R is hydrogen, a straight or branched alkyl having from 1 to 8 carbon atoms, or benzyl;
wherein R1 is
(a) phenyl which is unsubstituted or is substituted with from one to three substituents selected from:
phenyl,
alkyl having from one to six carbon atoms and which is straight or branched,
alkoxy having from one to six carbon atoms and which is straight or branched,
phenoxy,
hydroxy,
fluorine,
chlorine,
bromine,
nitro,
trifluoromethyl,
--COOH,
--COOalkyl wherein alkyl has from one to four carbon atoms and which is straight or branched,
--(CH2)p NR4 R5 wherein p is zero or one, and each of R4 and R5 is hydrogen or a straight or branched alkyl group having one to four carbon atoms;
(b) 1- or 2-naphthyl which is unsubstituted or substituted with one to three substituents selected from
phenyl,
alkyl having from one to six carbon atoms and which is straight or branched,
alkoxy having from one to six carbon atoms and which is straight or branched,
hydroxy,
phenoxy,
fluorine,
chlorine,
bromine,
nitro,
trifluoromethyl,
--COOH,
--COOalkyl wherein alkyl has from one to four carbon atoms and is straight or branched,
--(CH2)p NR4 R5 wherein p, R4, and R5 have the meanings defined above;
(c) the group ##STR14## wherein t is zero or one to four; w is zero or one to four with the proviso that the sum of t and w is not greater than five; R6 and R7 are independently selected from hydrogen or alkyl having for one to six carbon atoms, or when R6 is hydrogen, R7 can be selected from the groups defined for R8 ; and R8 is phenyl or phenyl substituted with from one to three substituents selected from straight or branched alkyl having from one to six carbon atoms, straight or branched alkoxy having from one to six carbon atoms, phenoxy, hydroxy, fluorine, chlorine, bromine, nitro, trifluoromethyl, --COOH, COOalkyl wherein alkyl has from one to four carbon atoms and is straight or branched, or --(CH2)p NR4 R5 wherein p, R4 and R5 have the meanings defined above;
(d) --(CH2)s --Q wherein s is a number of from zero to three and Q is a 5- or 6-membered monocyclic or fused bicyclic heterocycle containing at least one to four nitrogen, oxygen or sulfur atoms in at least one ring member; or
(e) a straight or branched hydrocarbon chain having from 1 to 20 carbon atoms and which is saturated or contains from one to three double bonds;
wherein each of R2 and R3 is
(a) hydrogen;
(b) the group ##STR15## wherein t, w, R6, R7 and R8 have the meanings defined above;
(c) a straight or branched hydrocarbon chain having from 1 to 20 carbon atoms and which is saturated or contains from one to three double bonds;
(d) an alkyl group having from one to six carbon atoms wherein the terminal carbon is substituted with hydroxy or --NR6 R7 wherein R6 and R7 have the meanings defined hereinabove;
(e) --(CH2)s Q wherein s and Q have the meanings defined above;
(f) phenyl or phenyl substituted with from one to three substituents selected from
phenyl,
alkyl having from one to six carbon atoms and which is straight or branched,
alkoxy having from one to six carbon atoms and which is straight or branched,
phenoxy,
hydroxy,
fluorine,
chlorine,
bromine,
nitro,
trifluoromethyl,
--COOH,
--COOalkyl wherein the alkyl moiety has from one to four carbon atoms and is straight or branched, or
--(CH2)p NR4 R5 wherein p, R4, and R5 have the meanings defined above; or
(g) NR1 R2 taken together form a monocyclic heterocyclic group selected from pyrrolidino, piperidino, morpholino, or piperazino, each of which is unsubstituted or substituted with one substituent selected from phenyl, straight or branched alkyl having from one to six carbon atoms; and pharmaceutically acceptable salts thereof; with the provisos:
(i) when each of R2 and R3 is the group ##STR16## R7 is hydrogen or alkyl having from one to six carbon atoms; (ii) at least one of R1, R2, and R3 is phenyl or substituted phenyl;
(iii) both R2 and R3 are not hydrogen at the same time;
(iv) when R1 is phenyl disubstituted on the 2,6-positions or trisubstituted on the 2,4,6-positions with alkyl having from one to four carbon atoms, or when R1 is phenyl disubstituted on the 2,6-positions with methoxy, neither of R2 or R3 is phenyl; and
(v) the following compounds wherein Ph means phenyl are excluded:
______________________________________
R.sub.1 R.sub.2 R.sub.3
______________________________________
C.sub.2 H.sub.5
H 4-(OC.sub.2 H.sub.5)Ph
C.sub.2 H.sub.5
H
##STR17##
C.sub.2 H.sub.5
H Ph
CH.sub.3 H Ph
CH.sub.2 CHCH.sub.2
H Ph
C.sub.4 H.sub.9
H Ph
PhCH.sub.2 H C.sub.3 H.sub.7
4(Cl)Ph H CH.sub.2 CHCH.sub.2
.sub.- i-C.sub.3 H.sub.7
H Ph
Ph CH.sub.3 CH.sub.3
Ph H Ph
Ph H n-C.sub.3 H.sub.7
Ph H n-C.sub.4 H.sub.9
Ph H
##STR18##
______________________________________
The present invention also provides pharmaceutical compositions containing compounds of the following general Formula II and the method of treating hypercholesterolemia and atherosclerosis using the compounds of the following Formula II: ##STR19## wherein X is sulfur or oxygen; wherein R is hydrogen, a straight or branched alkyl having from 1 to 8 carbon atoms, or benzyl;
wherein R1 is
(a) phenyl which is unsubstituted or is substituted with from one to three substituents selected from:
phenoxy,
hydroxy,
fluorine,
chlorine,
bromine,
nitro,
trifluoromethyl,
--COOH,
--COOalkyl wherein alkyl has from one to four carbon atoms and which is straight or branched,
--(CH2)p NR4 R5 wherein p is zero or one, and each of R4 and R5 is hydrogen or a straight or branched alkyl group having one to four carbon atoms;
(b) 1- or 2-naphthyl which is unsubstituted or substituted with one to three substituents selected from
phenyl,
alkyl having from one to six carbon atoms and which is straight or branched, alkoxy having from one to six carbon atoms and which is straight or branched,
hydroxy,
phenoxy,
fluorine,
chlorine,
bromine,
nitro,
trifluoromethyl,
--COOH,
--COOalkyl wherein alkyl has from one to four carbon atoms and is straight or branched,
--(CH2)p NR4 R5 wherein p, R4, and R5 have the meanings defined above;
(c) the group ##STR20## wherein t is zero or one to four; w is zero or one to four with the proviso that the sum of t and w is not greater than five; R6 and R7 are independently selected from hydrogen or alkyl having for one to six carbon atoms, or when R6 is hydrogen, R7 can be selected from the groups defined for R8 ; and R8 is phenyl or phenyl substituted with from one to three substituents selected from straight or branched alkyl having from one to six carbon atoms, straight or branched alkoxy having from one to six carbon atoms, phenoxy, hydroxy, fluorine, chlorine, bromine, nitro, trifluoromethyl, --COOH, COOalkyl wherein alkyl has from one to four carbon atoms and is straight or branched, or --(CH2)p NR4 R5 wherein p, R4 and R5 have the meanings defined above;
(d) --(CH2)s -Q wherein s is a number of from zero to three and Q is a 5- or 6-membered monocyclic or fused bicyclic heterocycle containing at least one to four nitrogen, oxygen or sulfur atoms in at least one ring member; or
(e) a straight or branched hydrocarbon chain having from 1 to 20 carbon atoms and which is saturated or contains from one to three double bonds;
wherein each of R2 and R3 is
(a) hydrogen;
(b) the group ##STR21## wherein t, w, R6, R7 and R8 have the meanings defined above;
(c) a straight or branched hydrocarbon chain having from 1 to 20 carbon atoms and which is saturated or contains from one to three double bonds;
(d) an alkyl group having from one to six carbon atoms wherein the terminal carbon is substituted with hydroxy or --NR6 R7 wherein R6 and R7 have the meanings defined hereinabove;
(e) --(CH2)s Q wherein s and Q have the meanings defined above;
(f) phenyl or phenyl substituted with from one to three substituents selected from
phenyl,
alkyl having from one to six carbon atoms and which is straight or branched,
alkoxy having from one to six carbon atoms and which is straight or branched,
phenoxy,
hydroxy,
fluorine,
chlorine,
bromine,
nitro,
trifluoromethyl,
--COOH,
--COOalkyl wherein the alkyl moiety has from one to four carbon atoms and is straight or branched, or
--(CH2)p NR4 R5 wherein p, R4, and R5 have the meanings defined above; or
(g) NR1 R2 taken together form a monocycl heterocyclic group selected from pyrrolidino, piperidino, morpholino, or piperazino, each of which is unsubstituted or substituted with one substituent selected from phenyl, straight or branched alkyl having from one to six carbon atoms; and pharmaceutically acceptable salts thereof; with the provisos:
(i) when each of R2 and R3 is the group ##STR22## R7 is hydrogen or alkyl having from one to six carbon atoms; (ii) at least one of R1, R2, and R3 is phenyl or substituted phenyl;
(iii) both R2 and R3 are not hydrogen at the same time.
The compounds of the present invention provide a novel class of aminosulfonyl carbamates which are ACAT inhibitors rendering them useful in treating hypercholesterolemia and atherosclerosis.
Illustrative examples of straight or branched saturated hydrocarbon chains having from 1 to 20 carbon atoms include methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, tert-butyl, n-pentyl, isopentyl, n-hexyl, n-heptyl, n-octyl, n-undecyl, n-dodecyl, n-hexadecyl, 2,2-dimethyldodecyl, 2-tetradecyl, and n-octadecyl groups.
Illustrative examples of straight or branched hydrocarbon chains having from 1 to 20 carbon atoms and having from 1 to 3 double bonds include ethenyl, 2-propenyl, 2-butenyl, 3-pentenyl, 2-octenyl, 5-nonenyl, 4-undecenyl, 5-heptadecenyl, 3-octadecenyl, 9-octadecenyl, 2,2-dimethyl-11-eicosenyl, 9,12-octadecadienyl, and hexadecenyl.
Straight or branched alkoxy groups having one to six carbon atoms include, for example, methoxy, ethoxy, n-propoxy, t-butoxy, and pentyloxy.
Straight or branched alkyl groups having from one to six carbon atoms include, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, n-pentyl, n-hexyl, and tert-butyl.
A 5- or 6-membered monocyclic or fused bicyclic heterocycle is a monocyclic or fused bicyclic aromatic ring containing at least one to four heteroatoms in at least one ring, such as nitrogen, oxygen, or sulfur or a combination thereof. Such a heterocyclic group includes, for example, thienyl, benzothienyl, furanyl, benzofuranyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, pyrazolyl, isothiazolyl, thiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, imidazolyl, benzothiazolyl, indolyl, quinolinyl, isoquinolinyl, or N-oxides of heterocycle containing a nitrogen atom.
More specifically, such a heterocycle may be a 2- or 3-thienyl; 2- or 3-furanyl; 2-, or 3-, or 4-pyridyl or 2-, or 3-, or 4-pyridyl-N-oxide; 2-, 4-, or 5-pyrimidinyl; 3- or 4-pyridazinyl; 2-pyrazinyl; 2-pyrazinyl-N-oxide; 2- or 3-pyrrolyl; 3-, 4-, or 5-pyrazolyl; 2-, 4-, or 5-thiazolyl; 3-, 4-, or 5-isoxazolyl; 2-, 4-, or 5-oxazolyl; 3-, 4-, or 5-isothiazolyl; 5-tetrazolyl; 3- or 5-(1,2,4,-)triazolyl; 4- or 5-(1,2,3-)triazolyl; 2-, 4-, or 5-imidazolyl; 2-, 3-, 4-, 5-, 6-, or 7-indolyl; 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolinyl; 1 -, 3-, 4-, 5-, 6-, 7-, or 8-isoquinolinyl; 2-, 4-, 5-, 6-, or 7-benzothiazolyl; or 2-, 3-, 4-, 5-, 6-, or 7-benzothienyl.
Preferred compounds of general Formulas I and II are those wherein one of R1, R2, and R3 is phenyl disubstituted in the 2,6-positions. More preferably R1 and R2 are 2,6-disubstituted phenyl and R3 is hydrogen. Compounds wherein R1 is 2,6-disubstituted phenyl and R2 and R3 are a straight or branched hydrocarbon chain having from 1 to 20 carbon atoms, and more preferably, 6 to 18 carbon atoms, and which is saturated or contains from 1 to 3 double bonds are also preferred.
Pharmaceutically acceptable salts of the compounds of Formula I are also included as a part of the present invention.
The base salts may be generated from compounds of Formula I and Formula II by reaction of the latter with one equivalent of a suitable nontoxic, pharmaceutically acceptable base followed by evaporation of the solvent employed for the reaction and recrystallization of the salt, if required. The compounds of Formula I may be recovered from the base salt by reaction of the salt with an aqueous solution of a suitable acid such as hydrobromic, hydrochloric, or acetic acid, or by reaction with a suitable alkylating agent such as an alkyl halide, e.g., methyl iodide or benzyl bromide.
Suitable bases for forming base salts of the compounds of this invention include amines such as triethylamine or dibutylamine, or alkali metal bases and alkaline earth metal bases. Preferred alkali metal hydroxides and alkaline earth metal hydroxides as salt formers are the hydroxides of lithium, sodium, potassium, or calcium. The class of bases suitable for the formation of nontoxic, pharmaceutically acceptable salts is well known to practitioners of the pharmaceutical formulation arts. See, for example, Stephen N. Berge, et al, J Pharm Sciences 66:1-19 (1977).
Suitable acids for forming acid salts of the compounds of Formulas I and II containing a basic group include, but are not necessarily limited to acetic, benzoic, benzenesulfonic, tartaric, hydrobromic, hydrochloric, citric, fumaric, gluconic, glucuronic, glutamic, lactic, malic, maleic, methanesulfonic, pamoic, salicylic, stearic, succinic, sulfuric, and tartaric acids. The acid addition salts are formed by procedures well known in the art.
Certain compounds of the present invention may also exist in different stereoisomeric forms by virtue of the presence of asymmetric centers in the compound. The present invention contemplates all stereoisomers may be obtained, if desired, by methods known in the art as, for example, the separation of stereoisomers in chiral chromatographic columns.
Further, the compounds of this invention may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of this invention.
As shown by the data presented below in Table 1, the compounds of the present invention are potent inhibitors of the enzyme acyl-CoA: cholesterol acyltransferase (ACAT), and are thus effective in inhibiting the esterification and transport of cholesterol across the intestinal cell wall. The compounds of the present invention are thus useful in pharmaceutical formulations for the treatment of hypercholesterolemia or atherosclerosis.
The ability of representative compounds of the present invention to inhibit ACAT was measured using an in vitro test more fully described in F. J. Field and R. G. Salone, Biochemica et Biophysica 712:557-570 (1982). The test assesses the ability of a test compound to inhibit the acylation of cholesterol by oleic acid by measuring the amount of radiolabeled cholesterol oleate formed from radiolabeled oleic acid in a tissue preparation containing rabbit intestinal microsomes.
The data appear in Table 1 where they are expressed as IC50 values; i. e., the concentration of test compound required to inhibit the activity of the enzyme by 50%.
TABLE 1
______________________________________
IAI
IC.sub.50
Example No. (μM)
______________________________________
1 >100
2 33
3 82
4 15
5 11.4
6 16.8
7 21.8
8 19
9 11
10 58
11 1.9
12 20
13 52
14 38
15 49
16 25.8
17 10.6
18 11.5
19 13.5
20 24.4
21 23.4
22 3.2
23 2.2
24 3.2
25 4.3
26 19.4
27 18.9
28 164
29 18
30 21
31 2.7
32 31
33 31
34 89
35 15
36 12
37 21
38 58
39 5.1
40 22
41 4.2
42 1.3
43 30.0
50 >100
51 >100
52 53
53 >100
54 43
56 >25
57 1.9
58 4.6
______________________________________
In one in vivo screen designated APCC, male Sprague-Dawley rats (200 to 225 g) were randomly divided into treatment groups and dosed at 4 PM with either vehicle (CMC/Tween) or suspensions of compounds in vehicle. The normal chow diet was then replaced with a high fat, high cholesterol diet with 0.5% cholic acid. The rats consumed this diet ad libitum during the night and were sacrificed at 8 AM to obtain blood samples for cholesterol analysis using standard procedures. Statistical differences between mean cholesterol values for the same vehicle were determined using analysis of variance followed by Fisher's least significant test. The results of this trial for representative compounds of the present invention appear in Table 2. The compounds were dosed at 30 mg/kg unless otherwise noted.
TABLE 2
______________________________________
Compound of Example
% Change (mg/dl)
______________________________________
1 --
2 0
3 -55
4 -77
5* -35
6* -57
7* -32
8* -26
9* -3
10 -67
11 -57
12 -43
13 +8
14* -55
15* -29
16* -65
17* -46
18* -42
19* -56
20* -54
21* -33
22 -4
23 -42
24 -19
25 -40
26 -52
27 -29
28 -13
29 -55
30 +2
31 0
32 -10
33 -22
34 -4
35 -76
36 -70
37 -58
38 -70
39 -60
40 -60
41 -62
42 -74
43 -8
50 -14
51 -11
52 -53
53 -21
54 -77
56 -39
57 -66
58 +4
______________________________________
*Indicates dosed at 50 mg/kg
In therapeutic use as agents for treating hypercholesterolemia or atherosclerosis, the compounds of Formula I or pharmaceutically acceptable salts thereof are administered to the patient at dosage levels of from 250 to 3000 mg per day. For a normal human adult of approximately 70 kg of body weight, this translates into a dosage of from 5 to 40 mg/kg of body weight per day. The specific dosages employed, however, may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the activity of the compound being employed. The determination of optimum dosages for a particular situation is within the skill of the art.
For preparing the pharmaceutical compositions from the compounds of this invention, inert, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, and cachets.
A solid carrier can be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or tablet disintegrating agents; it can also be an encapsulating material.
In powders, the carrier is a finely divided solid which is in a mixture with the finely divided active component. In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
Powders and tablets preferably contain between about 5% to about 70% by weight of the active ingredient. Suitable carriers are magnesium dicarbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low-melting wax, cocoa butter, and the like.
The term "preparation" is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component (with or without carriers) is surrounded by a carrier, which is thus in association with it. In a similar manner cachets are also included.
Tablets, powders, cachets, and capsules can be used as solid dosage forms suitable for oral administration.
Liquid form preparations include solutions, suspensions, or emulsions suitable for oral administration. Aqueous solutions for oral administration can be prepared by dissolving the active compound in water and adding suitable flavorants, coloring agents, stabilizers, and thickening agents as desired. Aqueous suspensions for oral use can be made by dispersing the finely divided active component in water together with a viscous material such as natural or synthetic gums, resins, methyl cellulose, sodium carboxymethylcellulose, and other suspending agents known to the pharmaceutical formulation art.
Preferably, the pharmaceutical preparation is in unit dosage form. In such form, the preparation is divided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation containing discrete quantities of the preparation, for example, packeted tablets, capsules, and powders in vials or ampoules. The unit dosage form can also be a capsule, cachet, or tablet itself, or it can be the appropriate number of these packaged forms.
The compounds of general Formulas I and II are prepared as generally described in Chart I hereof.
An alcohol or thiol of the formula R1 XH is reacted with chlorosulfonyl isocyanate in an inert organic solvent such as THF, Et2 O, CH2 Cl2 at room temperature or preferably colder (≦0° C.). The resulting chlorosulfonyl (thio) carbamate may precipitate out of solution or it can be triturated with a non polar solvent such as hexanes. The chlorosulfonyl (thio) carbamate can be isolated or it can be used as is and reacted with an amine of the formula NHR2 R3 in an inert organic solvent such as those mentioned above at ambient temperature in the presence of an acid scavenger such as triethylamine. The oxysulfonyl (thio) carbamate thus formed can be converted to its base salt by reacting with an appropriate metal or amine base. The base salt can then be reacted with an appropriate alkylating agent such as methyl iodide or benzyl bromide.
The alcohols R1 OH, thiols, R1 SH, and amines NHR2 R3 used in preparing the compounds of this invention are known in the art or are prepared by procedures generally known in the art.
The specific examples set forth below further illustrate the preparation of compounds of general Formula I and Formula II.
A solution of methyl(chlorosulfonyl) carbamate (5.0 g, 28.8 mmol) in 60 mL THF was added dropwise to a solution of 2,6-diisopropylaniline (5.11 g, 28.8 mmol) and excess triethylamine (˜5 mL) in 100 mL THF at room temperature under an atmosphere of N2. The mixture was stirred for 72 hrs, concentrated in vacuo and the residue was partitioned between 1N HCl and EtOAc. The organic layer was dried with MgSO4, filtered and evaporated to give an orange oil which was triturated with 10% EtOAc/hexanes to give 5.93 g (65%) of an off-white solid, mp 152-155° C.
A solution of dodecyl(chlorosulfonyl) carbamate (5.0 g, 15.2 mmol) in 70 mL THF was added dropwise to a solution of 2,6-diisopropylaniline (2.70 g, 15.2 mmol) and excess triethylamine (˜5 mL) in 100 mL THF at room temperature under an atmosphere of N2. The mixture was stirred for 16 hrs, concentrated in vacuo and partitioned between 1N HCl and EtOAc. The organic layer was dried with MgSO4, filtered and concentrated to give an orange oil. Chromatography (SiO2, 5% EtOAc/hex) gave 5.86 g (82%) of an off-white solid, mp 82°-84° C. (hexanes).
A solution of 2,6-bis(1,1-dimethylethyl)-4-methoxyphenyl(chlorosulfonyl) carbamate (5.0 g, 13.2 mmol) in 80 mL THF was added dropwise to a solution of 2,2-diphenylethylamine (2.61 g, 13.2 mmol) and excess triethylamine (˜3 mL) in 100 mL THF at room temperature under an atmosphere of N2. The mixture was stirred for 72 hrs and then concentrated in vacuo. The residue was partitioned between 1N HCl and EtOAc. The organic layer was dried with MgSO4, filtered and evaporated to give a clear oil which was triturated with hexanes to give 5.36 g (75%) of an off-white solid, mp 132°-138° C.
When in the general procedure of Example 3, an appropriate amount of 2,6-diisopropylaniline was substituted for 2,2-diphenylethylamine, the title compound was obtained, mp 155°-158° C.
A solution of 2,6-bis(1,1-dimethylethyl)phenyl (chlorosulfonyl) carbamate (2.85 g, 8.2 mmol) in 70 mL Et2 O was added dropwise to a solution of diphenylmethylamine (1.50 g, 8.2 mmol) and triethylamine (1.25 mL, 9.0 mmol) in 80 mL Et2 O at -15° C. under an atmosphere of N2. The mixture was warmed to room temperature and stirred for 6 hrs and then washed with 1N HCl and water. The organic layer was dried with MgSO4, filtered and evaporated to give 3.60 g (89%) of an off-white solid, mp 162°-166° C.
When in the general procedure of Example 5, an appropriate amount of 2,6-diisopropylaniline was substituted for diphenylmethylamine, the title compound was obtained, mp 180°-181° C.
When in the general procedure of Example 5, an appropriate amount of 2,2-diphenylethylamine was substituted for diphenylmethylamine, the title compound was obtained, mp 147°-150° C.
When in general procedure of Example 5, an appropriate amount of aniline was substituted for diphenylmethylamine, the title compound was obtained, mp 169°-172° C.
When in general procedure of Example 5, an appropriate amount of dibenzylamine was substituted for diphenylamine, the title compound was obtained, mp 182°-183° C.
Solid NaH (0.68 g, 17.1 mmol) was added in portions to a solution of diphenylamine (2.41 g, 14.2 mmol) in 75 mL THF at room temperature under an atmosphere of N2. The mixture was stirred for 16 hrs and then a solution of 2,6-bis(1-methylethyl)phenyl (chlorosulfonyl) carbamate (5.0 g, 15.6 mmol) in 50 mL THF was added dropwise. The reaction mixture was stirred for an additional 4 hrs and then quenched with 10 mL 1N HCl, and partitioned between 1N HCl and EtOAc. The organic layer was dried with MgSO4, filtered, and evaporated to give a green oil which was triturated and recrystallized from hexane to give 3.21 g (50%) of the title compound as an off-white solid, mp 149°-151° C.
A solution of 2,6-bis(1-methylethyl)phenyl(chlorosulfonyl)carbamate (5.0 g, 15.66 mmoles) in 75 mL THF was added dropwise to a solution of di-n-butylamine (1.84 g, 14.2 mmoles) and excess triethylamine (˜2 mL) in 75 mL THF. This was then stirred for 16 hours and then partitioned between 1N HCl and EtOAc. The organic layer was dried with MgSO4, filtered, and evaporated to give a pale orange oil Chromatography (SiO2, 5% EtOAc/hexane) gave 1.64 g (25%) of the title compound as a white solid, mp 94°-97° C.
When in the general procedure of Example 11, an appropriate amount of dibenzylamine was substituted for di-n-butylamine, the title compound was obtained, mp 143°-146° C.
When in the general procedure of Example 11, an appropriate amount of 2-aminobenzimidazole was substituted for di-n-butylamine, the title compound was obtained, mp 159°-162° C.
When in the general procedure of Example 11, an appropriate amount of aniline was substituted for di-n-butylamine, the title compound was obtained, mp 165°-168° C.
When in the general procedure of Example 11, an appropriate amount of 2,2-diphenylethylamine was substituted for di-n-butylamine, the title compound was obtained, mp 103°-105° C.
When in the general procedure of Example 11, an appropriate amount of 2,6-diisopropylaniline was substituted for di-n-butylamine, the title compound was obtained, mp 172°-174° C.
When in the general procedure of Example 11, an appropriate amount of diphenylmethylamine was substituted for di-n-butylamine, the title compound was obtained, mp 185°-187° C.
A solution of 2,6-bis(1,1-dimethylethyl)-4-methylphenyl(chlorosulfonyl)carbamate (2.96 g, 8.2 mmoles) in 70 mL Et2 O was added dropwise to a solution of diphenylmethylamine (1.5 g, 8.2 mmoles) and 1.25 mL (10.0 mmoles) of triethylamine in 80 mL Et2 O at -15° C. under an atmosphere of N2. The mixture was allowed to warm to room temperature over 2 hours and then washed with 1N HCl and H2 O. The Et2 O layer was dried with MgSO4, filtered, and evaporated to give a pale yellow foam which was triturated with hexanes to give a white solid, mp 150°-152° C.
When in the procedure of Example 18, an appropriate amount of 2,6-diisopropylaniline was substituted for diphenylmethylamine, the title compound was obtained, mp 176°-178° C.
When in the general procedure of Example 18, an appropriate amount of 2,2-diphenylethylamine was substituted for diphenylmethylamine, the title compound was obtained. mp 139°-141° C.
When in the general procedure of Example 18, an appropriate amount of aniline was substituted for diphenylmethylamine, the title compound was obtained, mp 186°-188° C.
When in the general procedure of Example 18, an appropriate amount of di-n-butylamine was substituted for diphenylmethylamine, the title compound was obtained, mp 134°-135° C.
When in the general procedure of Example 18, an appropriate amount of di-n-pentylamine was substituted for diphenylmethylamine, the title compound was obtained, mp 107°-108° C.
When in the general procedure of Example 18, an appropriate amount of diisopropylamine was substituted for diphenylmethylamine, the title compound was obtained, mp 198°-199° C.
When in the general procedure of Example 18, an appropriate amount of di-n-hexylamine was substituted for diphenylmethylamine, the title compound was obtained, mp 66°-68° C.
When in the general procedure of Example 18, an appropriate amount of hexylamine was substituted for diphenylmethylamine, the title compound was obtained, mp 123°-128° C.
When in the general procedure of Example 18, an appropriate amount of N-methyl-2-phenylethylamine was substituted for diphenylmethylamine, the title compound was obtained, mp 140°-142° C.
When in the general procedure of Example 18, an appropriate amount of bis-3-(dimethylamino)propyl amine was substituted for diphenylmethylamine, the title compound was obtained. 1 H NMR (CDCl3) δ 8.05 (bs, 1H), 7.05 (s, 2H), 3.29 (m, 4H), 2.87 (m, 4H), 2.56 (s, 12H), 2.29 (s, 3H), 1.91 (m, 4H), 1.37 (s, 18H) ppm.
When in the general procedure of Example 18, an appropriate amount of N-methyl octylamine was substituted for diphenylmethylamine, the title compound was obtained, mp 65°-68° C.
When in the general procedure of Example 18, an appropriate amount of bis-[(tetrahydro-2-furanyl)methyl] amine was substituted for diphenylmethylamine, the title compound was obtained, mp 108°-111° C.
When in the general procedure of Example 18, an appropriate amount of di-n-octylamine was substituted for diphenylmethylamine, the title compound was obtained, mp 53°-55° C.
A solution of 2,6-bis(1,1-dimethylethyl)-4-methylphenyl(chlorosulfonyl)carbamate (5.0 g, 13.8 mmoles) in 70 mL THF was added dropwise to a solution of 2-(β-methylaminoethyl)pyridine (1.88 g, 13.8 mmoles) and excess triethylamine (˜2 mL) in 80 mL THF at room temperature under an atmosphere of N2. The solution was stirred for 16 hours and then concentrated in vacuo. The residue was partitioned between 1N HCl and EtOAc, the EtOAc layer dried with MgSO4, filtered, and evaporated to give a white solid which was then triturated with hexanes to give 5.00 g of the title compound, mp 178°-181° C.
Excess 1N NaOH (30 mL) was added to a suspension of 2,6-bis(1,1-dimethylethyl)-4-methylphenyl[[[methyl 2-(2-pyridinyl)ethyl]amino]sulfonyl]carbamate hydrochloride (2.75 g, 5.5 mmoles) in 50 mL EtOAc. The mixture was stirred for 16 hours, the organic layer separated, dried with MgSO4, filtered, and evaporated to give a clear oil which was triturated with hexanes to give the title compound as a white solid, mp 133°-136° C.
When in the general procedure of Example 18, an appropriate amount of di-n-decylamine was substituted for diphenylmethylamine, the title compound was obtained as a waxy white solid, mp 63°-65° C.
When in the general procedure of Example 11, an appropriate amount of diisopropylamine was substituted for di-n-butylamine, the title compound was obtained, mp 126°-131° C.
When in the general procedure of Example 11, an appropriate amount of N-isopropyl benzylamine was substituted for di-n-butylamine, the title compound was obtained, mp 156°-159° C.
When in the general procedure of Example 11, an appropriate amount of n-hexylamine was substituted for di-n-butylamine, the title compound was obtained, mp 105°-106.5° C.
When in the general procedure of Example 11, an appropriate amount of di-n-octylamine was substituted for di-n-butylamine, the title compound was obtained, mp 64°-67° C.
When in the general procedure of Example 11, an appropriate amount of N-isopropylcyclohexylamine was substituted for di-n-butylamine, the title compound was obtained, mp 133°-135° C.
When in the general procedure of Example 11, an appropriate amount of N-methyloctylamine was substituted for di-n-butylamine, the title compound was obtained, mp 32°-35° C.
When in the general procedure of Example 11, an appropriate amount of di-n-hexylamine was substituted for di-n-butylamine, the title compound was obtained, mp 57°-61° C.
When in the general procedure of Example 11, an appropriate amount of di-n-pentylamine was substituted for di-n-butylamine, the title compound was obtained, mp 69°-70° C.
When in the general procedure of Example 2, an appropriate amount of 2,4,6-trimethoxyaniline was substituted for 2,6-diisopropylaniline, the title compound was obtained, mp 133°-136° C.
The following Example 44 through 49 teach the preparation of intermediates useful in preparing final products of the present invention.
A solution of methanol (10.2 mL, 252 mmoles) in 15 mL toluene was added dropwise to a solution of chlorosulfonyl isocyanate (22.0 mL, 252 mmoles) in 75 mL toluene at 0° C. The cooling bath was removed and stirred for one-half hour at room temperature. This was then cooled to 0° C. and 65 mL ice cold hexanes was added. The white precipitate was collected by filtration and washed 2 times with a small amount of cold hexane to give 33.0 g of a white solid, mp 72°-74° C.
A solution of n-dodecyl alcohol (107 g, 52.4 mmoles) in 100 mL Et2 O was added dropwise to a solution of chlorosulfonyl isocyanate (5.0 mL, 57.4 mmoles) in 100 mL Et2 O at -15° C. under an atmosphere of N2. The resulting mixture was stirred for 2 hours and concentrated in vacuo. The residue was triturated with cold hexanes to give a white solid which was collected by filtration to give 19.12 g of a white solid, mp 62°-63° C.
A solution of 2,6-diisopropylphenol (37.1 mL, 0.2 moles) in 200 mL Et2 O was added dropwise to a solution of chlorosulfonyl isocyanate (17.4 mL, 0.2 moles)) in 200 mL Et2 O at -15° C. This was then stored at -15° C. under an atmosphere of N2 for 16 hours. Concentration gave an orange oil which was triturated with hexanes and quickly collected by filtration to give 55.64 g (87%) of product as a white solid.
A solution of 2,6-di-t-butylphenol (20.63 g, 0.1 mol) in 100 mL Et2 O was added dropwise to a solution of chlorosulfonyl isocyanate (8.7 mL, 0.1 moles) in 100 mL Et2 O at -15° C. (acetone/ice bath) under an atmosphere of N2. This was stirred for 1 hour and then concentrated in vacuo to leave a thick gel which was triturated with hexanes and filtered to give 28.60 g (82%) of the title compound as a white solid, mp 135°-137° C.
A solution of 2,6-di-t-butyl-4-methylphenol (22.04 g, 0.1 moles) in 100 mL Et2 O was added dropwise to a solution of chlorosulfonyl isocyanate (8.7 mL, 0.1 moles) in 100 mL Et2 O at -15° C. under an atmosphere of N2. This was stirred for 2 hours, concentrated and trituration of the resulting gel with hexanes gave 26.82 g (74%) of the title compound as a white solid.
A solution of 3,5-di-t-butyl-4-hydroxyanisole (30.0 g, 0.127 moles) in 200 mL Et2 O was added dropwise to a solution of chlorosulfonyl isocyanate (12.2 mL, 0.14 moles) in 250 mL Et2 O at -15° C. under an atmosphere of N2. This was stirred for 1 hour and then concentrated in vacuo to give 41.0 g of product as a thick gel which was used without further purification.
The examples set forth hereinbelow further illustrate the preparation of final products of the compounds of the present invention.
When in the procedure of Example 11 an appropriate amount of the amine listed below was substituted for di-n-butylamine the respective product listed below was obtained:
______________________________________
Example
No. Amine Product
______________________________________
50 Morpholine 2,6-Bis(1-methylethyl)-
phenyl ester(4-
morpholinylsulfonyl)-
carbamic acid;
.sup.1 H NMR (CDCl.sub.3) δ 7.9
(bs, 1H), 7.1(m, 3H),
3.7(t, 4H), 3.5(5,
4H), 3.0(m, 2H), 1.2
(d, 12H)ppm.
51 Piperidine 2,6-Bis(1-methylethyl)-
phenyl ester(1-
piperidinylsulfonyl)-
carbamic acid;
.sup.1 H NMR (CDCl.sub.3) δ 8.1
(bs, 1H), 7.1(m, 3H),
3.4(t, 4H), 3.0(m,
2H), 1.7(m, 4H), 1.6
(m, 2H), 1.2(d,
12H)ppm
52 Pyrrolidine 2,6-Bis(1-methylethyl)-
phenyl ester(1-
pyrrolidinylsulfonyl)-
carbamic acid;
.sup.1 H NMR (CDCl.sub.3) δ 7.8
(bs, 1H), 7.1(m, 3H),
3.6(t, 4H), 3.0(m,
2H), 1.9(t, 4H), 1.2
(d, 12H)ppm.
53 4-Methylpipera-
2,6-Bis(1-methylethyl)-
zine phenyl ester,
monohydrochloride[(4-
methyl-1-piperazinyl)-
sulfonyl]carbamic acid;
1H NMR (DMSO D.sub.6) δ 8.0
(s, 1H), 7.0(d, 3H),
3.3(m, 2H), 3.1(bs,
4H), 2.8(bs, 4H), 2.5
(s, 3H), 1.1(d,
12H)ppm.
54 2,3-Dihydroindole
2,6-Bis(1-methylethyl)-
phenyl ester[(2,3-
dihydro-1H-indol-1-
yl)sulfonyl[carbamic
acid; .sup.1 H NMR (CDCl.sub.3) δ
8.0(bs, 1H), 7.4(d,
1H), 7.2(m, 3H), 7.1
(m, 3H), 4.4(t, 2H),
3.1(t, 2H), 2.5(m,
2H), 1.0(d, 12H)ppm.
______________________________________
A solution of 2,6-diphenyl phenol (25.0 g, 101 mmol) in 250 mL ethyl ether was added dropwise to a solution of chlorosulfonyl isocyanate (9.7 mL, 112 μmol) in 100 mL hexane at -15° C. under an atmosphere of nitrogen. The resulting white suspension was allowed to warm to room temperature over 2 hours. Concentrated in vacuo and triturated with ice cold hexane. Vacuum filtration afforded the title compound as a white solid, mp 159°-162° C.
A solution of [1,1':3',1"-terphenyl]-2,-yl(chlorosulfonyl)carbamate (5.0 g, 12.9 mmol) in 75 mL tetrahydrofuran was added dropwise to a solution of 2,6-diisopropyl aniline (2.29 g, 12.9 mmol) and triethylamine (1.3 g, 12.9 mmol) in 100 mL tetrahydrofuran at -15° C. under an atmosphere of nitrogen. The resulting mixture was warmed to room temperature and stirred for 16 hours. Concentrated in vacuo and partitioned the residue between water and ethyl acetate. Dried the organic layer over MgSO4 and evaporated to give an off-white solid. Chromatography on silica gel gave the title compound, mp 166°-168° C.
A solution of the 2,6-bis(1-methylethyl)phenyl[(dibutylamino)sulfonyl]carbamate (5.5 g, 13.3 mmol) in 75 mL tetrahydrofuran was added dropwise to a suspension of sodium hydride (0.4 g, 80% dispersion in mineral oil, 13.3 mmol) in 50 mL tetrahydrofuran at 0° C. under an atmosphere of nitrogen. Stirred for 3 hours, gradually warming to room temperature. Concentrated in vacuo and triturated with hexanes to give the title compound, mp 162°-166° C.
1,8-Diazabicyclo[5.4.0]undec-7-ene (1.0 mL, 6.7 mmol) was added in one portion to a solution of 2,6-bis(1,1-dimethylethyl)phenyl[[(diphenylmethyl)amino]sulfonyl]carbamate (3.0 g, 6.1 mmol) and methyl iodide (0.95 g, 6.7 mmol) in 50 mL acetonitrile at room temperature and the resulting mixture was stirred for 16 hours. Partitioned between 1N HCl and ethyl acetate. Dried the organic layer over MgSO4, filtered, and evaporated to give an orange oil. Chromatography on silica gel gave the title compound, mp 175°-178° C.
Claims (8)
1. A compound of the formula
wherein X=oxygen or sulfur; R is hydrogen, a straight or branched alkyl group having from 1 to 8 carbon atoms, or benzyl;
wherein R1 is
(a) phenyl substituted with from one to three substituents selected from:
phenyl,
alkyl having from one to six carbon atoms and which is straight or branched,
alkoxy having from one to six carbon atoms and which is straight or branched,
phenoxy,
hydroxy,
fluorine,
bromine,
nitro,
trifluoromethyl,
--COOH,
--COOalkyl wherein alkyl has from one to four carbon atoms and which is straight or branched,
--(CH2)p NR4 R5 wherein p is zero or one, and each of R4 and R5 is hydrogen or a straight or branched alkyl group having one to four carbon atoms;
(b) 1- or 2-naphthyl which is unsubstituted or substituted with one to three substituents selected from
phenyl,
alkyl having from one to six carbon atoms and which is straight or branched,
alkoxy having from one to six carbon atoms and which is straight or branched,
phenoxy,
hydroxy,
fluorine,
chlorine,
bromine,
nitro,
trifluoromethyl,
--COOH,
--COOalkyl wherein alkyl has from one to four carbon atoms and is straight or branched,
--(CH2)p NR4 R5 wherein p, R4, and R5 have the meanings defined above; or
(c) --(CH2)2 --Q wherein s is a number of form zero to three and Q is a 4- or 6-membered monocyclic or fused bicyclic heterocycle containing at least one to four nitrogen, oxygen or sulfur atoms in at least one ring member;
wherein each of R2 and R3 is
(a) hydrogen;
(b) the group ##STR24## wherein t is zero or one to four; w is zero or one to four with the proviso that the sum of t and w is not greater than five; R6 and R7 are independently selected from hydrogen or alkyl having for one to six carbon atoms, or when R6 is hydrogen, R7 can be selected from the groups defined for R8 ; and R8 is phenyl or phenyl substituted with from one to three substituents selected from straight or branched alkyl having from one to six carbon atoms, straight or branched alkoxy having from one to six carbon atoms, phenoxy, hydroxy, fluorine, chlorine, bromine, nitro, trifluoromethyl, --COOH, COOalkyl wherein alkyl has from one to four carbon atoms and is straight or branched, or --(CH2)p NR4 R5 wherein p, R4 and R5 have the meanings defined above;
(c) a straight or branched hydrocarbon chain having from 1 to 20 carbon atoms and which is saturated or contains from one to three double bonds;
(d) an alkyl group having from one to six carbon atoms wherein the terminal carbon is substituted with hydroxy or --NR6 R7 wherein R6 and R7 have the meanings defined hereinabove;
(e) --(CH2)s Q wherein s and Q have the meanings defined above;
(f) phenyl or phenyl substituted with from one to three substituents selected from phenyl,
alkyl having form one to six carbon atoms and which is straight or branched,
alkoxy having from one to six carbon atoms and which is straight or branched,
phenoxy,
hydroxy,
fluorine,
chlorine,
bromine,
nitro,
trifluoromethyl,
--COOH,
--COOalkyl wherein the alkyl moiety has from one to four carbon atoms and is straight or branched, or
--(CH2)p NR4 R5 wherein p, R4, and R5 have the meanings defined above; or
(g) NR2 R3 taken together form a monocyclic heterocyclic group selected form pyrrolidino, piperidino, morpholino, or piperazino, each of which is unsubstituted or substituted with one substituent selected from phenyl, straight or branched alkyl having from one to six carbon atoms; and pharmaceutically acceptable salts thereof; with the provisos:
(i) when each of R2 and R3 is the group ##STR25## R7 is hydrogen or alkyl having from one to six carbon atoms; (ii) at least one of R1,R2, and R3 is phenyl or substituted phenyl;
(iii) both R2 and R3 are not hydrogen at the same time;
(iv) when R1 is phenyl disubstituted on the 2,6-positions with alkyl having form one to four carbon atoms or with methoxy, or trisubstituted on the 2,4,6-positions with alkyl having from one t four carbon atoms, neither of R2 or R3 is phenyl; and
(v) the following compound wherein Ph means phenyl is excluded:
2. A compound of claim 1 wherein R1 is disubstituted in the 2,6-positions.
3. A compound of claim 2 wherein R2 is substituted or unsubstituted phenyl.
4. A compound of claim 3 wherein R2 is phenyl disubstituted in the 2,6-positions.
5. A compound of claim 4 wherein R3 is hydrogen.
6. A compound of claim 1 which is:
2,6-Bis(1,1-dimethylethyl)-4-methoxyphenyl[[(2,2-diphenylethyl)amino]sulfonyl]carbamate,
2,6-Bis(1,1-dimethylethyl)-4-methoxy phenyl [[[2,6-bis(1-methylethyl)phenyl]amino]sulfonyl]carbamate,
2,6-Bis(1,1-dimethylethyl)phenyl[[(diphenylmethyl)amino]sulfonyl]carbamate,
2,6-Bis(1,1-dimethylethyl)phenyl [[[2,6-bis(1-methylethyl)phenyl]amino]sulfonyl]carbamate,
2,6-Bis(1,1-dimethylethyl)-phenyl [[(2,2-diphenylethyl)amino]sulfonyl]carbamate,
2,6-Bis(1,1-dimethylethyl)phenyl [[bis(phenylmethyl)amino]sulfonyl]carbamate,
2,6-bis(1-methylethyl)phenyl[(diphenylamino)sulfonyl]carbamate,
2,6-Bis(1-methylethyl)phenyl[(dibutylamino)sulfonyl]carbamate,
2,6-Bis(1-methylethyl)phenyl[[bis(phenylmethyl)amino]sulfonyl]carbamate,
2,6-Bis(1-methylethyl)phenyl[(1H-benzimidazol-2-ylamino)sulfonyl]carbamate,
2,6-Bis(1-methylethyl)phenyl[[2,2-diphenylethyl)amino]sulfonyl]carbamate,
2,6-Bis(1-methylethyl)phenyl[[[2,6-bis(1-methylethyl)phenyl]amino]sulfonyl]carbamate,
2,6-Bis(1-methylethyl)phenyl[[(diphenylmethyl)amino]sulfonyl]carbamate,
2,6-Bis(1,1-dimethylethyl)-4-methylphenyl[κ(diphenylmethyl)amino[sulfonyl]carbamate,
2,6-Bis(1,1-dimethylethyl)-4-methylphenyl[[[bis(2,6-bis(1-methylethyl)phenyl]amino]sulfonyl]carbamate,
2. 6-Bis(1,1-dimethylethyl)-4-methylphenyl[[(2,2-diphenylethyl)amino]sulfonyl]carbamate,
2,6-Bis(1,1-dimethylethyl)-4-methylphenyl[(dibutylamino)sulfonyl]carbamate,
2,6-Bis(1,1-dimethylethyl)4-methylphenyl[(dipentylamino)sulfonyl]carbamate,
2,6-Bis(1,1-dimethylethyl)-4methylphenyl[[bis(1-methylethyl)amino]sulfonyl]carbamate,
2,6-Bis(1,1-dimethylethyl)-4-methylphenyl[(dihexylamino)sulfonyl]carbamate,
2,6-Bis(1,1-dimethylethyl)-4-methylphenyl[(hexylamino)sulfonyl]carbamate,
2,6-Bis(1,1-dimethylethyl)-4-methylphenyl[[methyl(2-phenylethyl)amino]sulfonyl]carbamate,
2,6-Bis(1,1-dimethylethyl)-4-methylphenyl[κ[bis-3-(dimethylamino)propyl]amino]sulfonyl]carbamate,
2,6-Bis(1,1-dimethylethyl)-4-methylphenyl[(methyl octyl amino)sulfonyl]carbamate,
2,6-Bis(1,1-dimethylethyl)-4-methyl[[bis[(tetrahydro-2-furanyl)methyl]amino]sulfonyl]carbamate,
2,6-Bis(1,1-dimethylethyl)-4-methylphenyl[(dioctylamino)sulfonyl]carbamate,
2,6-Bis(1,1-dimethylethyl)-4-methylphenyl[[[methyl 2-(2-pyridinyl)ethyl]amino]sulfonyl]carbamate, hydrochloride salt,
2,6-Bis(1,1-dimethylethyl)-4-methylphenyl[[[methyl 2-(2-pyridinyl)ethyl]amino]sulfonyl]carbamate, sodium salt,
2,6-Bis(1,1-dimethylethyl)-4-methylphenyl[(dodecylamino)sulfonyl]carbamate,
2,6-Bis(1-methylethyl)phenyl[[bis(1-methylethyl)amino]sulfonyl]carbamate,
2,6-Bis(1-methylethyl)phenyl[[(1-methylethyl)phenylmethyl)amino]sulfonyl]carbamate,
2,6-Bis(1-methylethyl)phenyl[(hexylamino)sulfonyl]carbamate,
2. 6-Bis(1-methylethyl)phenyl[(dioctylamino)sulfonyl]carbamate,
2,6-Bis(1-methylethyl)phenyl[[cyclo-hexyl (1-methylethyl)amino]sufonyl]carbamate,
2,6-Bis(1-methylethyl)phenyl[(methyloctylamino)sulfonyl]carbamate,
2,6-Bis(1-methylethyl)phenyl[(dihexylamino)sulfonyl]carbamate,
2,6-Bis(1-methylethyl)phenyl ester(4-morpholinylsulfonyl)carbamic acid,
2,6-Bis(1-methylethyl)phenyl ester(1-piperidinylsulfonyl)carbamic acid,
2,6-Bis(1-methylethyl)phenyl ester(1-pyrrolidinylsulfonyl)carbamic acid,
2,6-Bis(1-methylethyl)phenyl ester, monohydrochloride[(4-methyl-1-piperazinyl)sulfonyl]carbamic acid,
2,6-Bis(1-methylethyl)-phenyl ester[(2,3-dihydro-1H-indol-1-1-yl)sulfonyl]carbamic acid,
2,6-Bis(1-methylethyl)phenyl[(dibutylamino)sulfonyl]carbamate monosodium salt,
[1,1:3',1"-Terphenyl]-2'-yl[[[2,6-bis(1-methylethyl)phenyl]amino]sulfonyl ]carbamate, and
2,6-Bis(1,1-dimethylethyl)phenyl[[(diphenylmethyl)amino]sulfonyl]methyl carbamate.
Priority Applications (16)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/747,031 US5254715A (en) | 1990-11-07 | 1991-08-19 | Aminosulfonyl carbamates |
| AU89509/91A AU651155B2 (en) | 1990-11-07 | 1991-11-05 | Aminosulfonyl carbamates |
| EP91920248A EP0592439B1 (en) | 1990-11-07 | 1991-11-05 | Aminosulfonyl carbamates |
| PCT/US1991/008215 WO1992008693A1 (en) | 1990-11-07 | 1991-11-05 | Aminosulfonyl carbamates |
| NZ240480A NZ240480A (en) | 1990-11-07 | 1991-11-05 | Aminosulphonyl carbamates and pharmaceutical compositions thereof |
| DE69133299T DE69133299T2 (en) | 1990-11-07 | 1991-11-05 | AMINOSULFONYLCARBAMATE |
| DK91920248T DK0592439T3 (en) | 1990-11-07 | 1991-11-05 | Aminosulfonyl carbamates |
| JP50093192A JP3484193B2 (en) | 1990-11-07 | 1991-11-05 | Aminosulfonyl carbamate |
| AT91920248T ATE246171T1 (en) | 1990-11-07 | 1991-11-05 | AMINOSULFONYL CARBAMATES |
| ES91920248T ES2201048T3 (en) | 1990-11-07 | 1991-11-05 | AMINOSULPHONYL CARBAMATES. |
| CA002094807A CA2094807A1 (en) | 1990-11-07 | 1991-11-05 | Aminosulfonyl carbamates |
| MX9101957A MX9101957A (en) | 1990-11-07 | 1991-11-06 | AMINOSULFONYL CARBAMATES |
| IE387591A IE913875A1 (en) | 1990-11-07 | 1991-11-06 | Aminosulfonyl carbamates |
| PT99436A PT99436B (en) | 1990-11-07 | 1991-11-06 | PROCESS FOR THE PREPARATION OF AMINO-SULFONYL-CARBAMATE DERIVATIVES AND PHARMACEUTICAL COMPOUNDS CONTAINING THEM |
| US08/075,083 US5336690A (en) | 1990-11-07 | 1993-06-10 | Aminosulfonyl carbamates composition and method of use to treat hypercholesterolemia and atherosclerosis |
| JP2000170387A JP3468738B2 (en) | 1990-11-07 | 2000-06-07 | A therapeutic agent for hypercholesterolemia or atherosclerosis |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61048790A | 1990-11-07 | 1990-11-07 | |
| US07/747,031 US5254715A (en) | 1990-11-07 | 1991-08-19 | Aminosulfonyl carbamates |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US61048790A Continuation-In-Part | 1990-11-07 | 1990-11-07 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US08/075,083 Division US5336690A (en) | 1990-11-07 | 1993-06-10 | Aminosulfonyl carbamates composition and method of use to treat hypercholesterolemia and atherosclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US5254715A true US5254715A (en) | 1993-10-19 |
Family
ID=27086264
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US07/747,031 Expired - Lifetime US5254715A (en) | 1990-11-07 | 1991-08-19 | Aminosulfonyl carbamates |
| US08/075,083 Expired - Fee Related US5336690A (en) | 1990-11-07 | 1993-06-10 | Aminosulfonyl carbamates composition and method of use to treat hypercholesterolemia and atherosclerosis |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US08/075,083 Expired - Fee Related US5336690A (en) | 1990-11-07 | 1993-06-10 | Aminosulfonyl carbamates composition and method of use to treat hypercholesterolemia and atherosclerosis |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US5254715A (en) |
| EP (1) | EP0592439B1 (en) |
| JP (2) | JP3484193B2 (en) |
| AT (1) | ATE246171T1 (en) |
| AU (1) | AU651155B2 (en) |
| CA (1) | CA2094807A1 (en) |
| DE (1) | DE69133299T2 (en) |
| DK (1) | DK0592439T3 (en) |
| ES (1) | ES2201048T3 (en) |
| IE (1) | IE913875A1 (en) |
| MX (1) | MX9101957A (en) |
| NZ (1) | NZ240480A (en) |
| PT (1) | PT99436B (en) |
| WO (1) | WO1992008693A1 (en) |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5491170A (en) * | 1994-12-19 | 1996-02-13 | Warner-Lambert Company | β-carboxy sulfonamide ACAT inhibitors |
| US5585519A (en) * | 1994-05-04 | 1996-12-17 | Ciba-Geigy Corporation | Microbicides |
| US5629341A (en) * | 1995-04-12 | 1997-05-13 | The Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of viruses and cancers |
| WO1997019091A1 (en) * | 1995-11-23 | 1997-05-29 | Laboratori Baldacci S.P.A. | Novel geranylgeranyl-derivatives, process for the preparation thereof and related pharmaceutical compositions |
| US5932609A (en) * | 1995-04-12 | 1999-08-03 | The Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of cancers |
| US6177460B1 (en) | 1995-04-12 | 2001-01-23 | The Procter & Gamble Company | Method of treatment for cancer or viral infections |
| US6194463B1 (en) * | 1997-02-25 | 2001-02-27 | Novartis Crop Protection, Inc. | N-sulphonyl and N-sulphinyl amino acid amides as microbicides |
| EP1236468A1 (en) * | 2001-02-12 | 2002-09-04 | Warner-Lambert Company | Sulfonylaminocarbonyl derivatives for the treatment of nuclear factor-kappa B mediated diseases and disorders |
| EP1281399A2 (en) * | 2001-08-01 | 2003-02-05 | Warner-Lambert Company | Dual inhibitors of wax ester and cholesteryl ester synthesis for inhibiting sebum production |
| US6686391B2 (en) | 1995-08-04 | 2004-02-03 | University Of Arizona Foundation | N-chlorophenylcarbamate and N-chlorophenylthiocarbamate compositions |
| WO2006135860A1 (en) * | 2005-06-10 | 2006-12-21 | Elixir Pharmaceuticals, Inc. | Sulfonamide compounds and uses thereof |
| US20070270473A1 (en) * | 2005-06-10 | 2007-11-22 | Saunders Jeffrey O | Sulfonamide Compounds and Uses Thereof |
| US20150291571A1 (en) * | 2010-11-16 | 2015-10-15 | Texas Heart Institute | Agonists that enhanced binding of integrin-expressing cells to integrin receptors |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002240235B2 (en) * | 2001-01-30 | 2006-07-06 | Merck & Co., Inc. | Acyl sulfamides for treatment of obesity, diabetes and lipid disorders |
| US7049333B2 (en) | 2002-06-04 | 2006-05-23 | Sanofi-Aventis Deutschland Gmbh | Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis |
| US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
| US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
| US7279576B2 (en) | 2002-12-31 | 2007-10-09 | Deciphera Pharmaceuticals, Llc | Anti-cancer medicaments |
| JP5197016B2 (en) | 2004-12-23 | 2013-05-15 | デシファラ ファーマスーティカルズ， エルエルシー | Enzyme modulators and therapy |
| US8188113B2 (en) | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| US7790756B2 (en) | 2006-10-11 | 2010-09-07 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
| EP2146717A4 (en) | 2007-04-20 | 2010-08-11 | Deciphera Pharmaceuticals Llc | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
| BRPI0920765A2 (en) | 2008-10-29 | 2015-08-18 | Deciphera Pharmaceuticals Llc | Cilopropane amides and analogs that exhibit anticancer and antiproliferative activities |
| US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| MX2022001863A (en) | 2019-08-12 | 2022-05-30 | Deciphera Pharmaceuticals Llc | Ripretinib for treating gastrointestinal stromal tumors. |
| TW202122082A (en) | 2019-08-12 | 2021-06-16 | 美商迪賽孚爾製藥有限公司 | Methods of treating gastrointestinal stromal tumors |
| IL293864A (en) | 2019-12-30 | 2022-08-01 | Deciphera Pharmaceuticals Llc | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
| LT4084778T (en) | 2019-12-30 | 2024-01-25 | Deciphera Pharmaceuticals, Llc | Amorphous kinase inhibitor formulations and methods of use thereof |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE940292C (en) * | 1952-07-01 | 1956-03-15 | Hoechst Ag | Process for the preparation of condensation products containing nitrogen and sulfur |
| EP0123763A2 (en) * | 1983-03-30 | 1984-11-07 | Ciba-Geigy Ag | Process for sizing paper with anionic hydrophobic sizing agents and cationic retention agents |
-
1991
- 1991-08-19 US US07/747,031 patent/US5254715A/en not_active Expired - Lifetime
- 1991-11-05 WO PCT/US1991/008215 patent/WO1992008693A1/en active IP Right Grant
- 1991-11-05 CA CA002094807A patent/CA2094807A1/en not_active Abandoned
- 1991-11-05 ES ES91920248T patent/ES2201048T3/en not_active Expired - Lifetime
- 1991-11-05 DE DE69133299T patent/DE69133299T2/en not_active Expired - Fee Related
- 1991-11-05 AT AT91920248T patent/ATE246171T1/en not_active IP Right Cessation
- 1991-11-05 EP EP91920248A patent/EP0592439B1/en not_active Expired - Lifetime
- 1991-11-05 DK DK91920248T patent/DK0592439T3/en active
- 1991-11-05 AU AU89509/91A patent/AU651155B2/en not_active Ceased
- 1991-11-05 JP JP50093192A patent/JP3484193B2/en not_active Expired - Fee Related
- 1991-11-05 NZ NZ240480A patent/NZ240480A/en not_active IP Right Cessation
- 1991-11-06 IE IE387591A patent/IE913875A1/en not_active Application Discontinuation
- 1991-11-06 PT PT99436A patent/PT99436B/en not_active IP Right Cessation
- 1991-11-06 MX MX9101957A patent/MX9101957A/en not_active IP Right Cessation
-
1993
- 1993-06-10 US US08/075,083 patent/US5336690A/en not_active Expired - Fee Related
-
2000
- 2000-06-07 JP JP2000170387A patent/JP3468738B2/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE940292C (en) * | 1952-07-01 | 1956-03-15 | Hoechst Ag | Process for the preparation of condensation products containing nitrogen and sulfur |
| EP0123763A2 (en) * | 1983-03-30 | 1984-11-07 | Ciba-Geigy Ag | Process for sizing paper with anionic hydrophobic sizing agents and cationic retention agents |
Non-Patent Citations (8)
| Title |
|---|
| Chem. Ber. 96, 56 67 (1963), R. Graf, Reactions with N carbonylsulfamic acid chloride 1 , II 2 L: Alcohols and phenols , * |
| Chem. Ber. 96, 56-67 (1963), R. Graf, "Reactions with N-carbonylsulfamic acid chloride [1], II [2]L: Alcohols and phenols", |
| J. Med. Chem. 8, 781 784 (1965), J. McFarland, Sulfamylurea Hypoglycemic Agents. III. Tetrasubstituted Sulfamylureas and N Sulfamylcarbamates . * |
| J. Med. Chem. 8, 781-784 (1965), J. McFarland, "Sulfamylurea Hypoglycemic Agents. III. Tetrasubstituted Sulfamylureas and N-Sulfamylcarbamates". |
| Phosphorus and Sulfur 19(2), 167 172 (1984), M. Hedayatullah Syntheses a l aide d Heterocumulenes . * |
| Phosphorus and Sulfur 19(2), 167-172 (1984), M. Hedayatullah "Syntheses a l'aide d'Heterocumulenes". |
| Tetrahedron Letters 24, (30) 3091 3094 (1983), J. Montero, Selective Synthesis of Sulfonylureas and Carboxysulfamides a Novel Route to Oxazolidinones . * |
| Tetrahedron Letters 24, (30) 3091-3094 (1983), J. Montero, "Selective Synthesis of Sulfonylureas and Carboxysulfamides a Novel Route to Oxazolidinones". |
Cited By (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5728875A (en) * | 1994-05-04 | 1998-03-17 | Novartis Corporation | Microbicides |
| US5585519A (en) * | 1994-05-04 | 1996-12-17 | Ciba-Geigy Corporation | Microbicides |
| US5491170A (en) * | 1994-12-19 | 1996-02-13 | Warner-Lambert Company | β-carboxy sulfonamide ACAT inhibitors |
| US6498188B1 (en) | 1995-04-12 | 2002-12-24 | The Procter & Gamble Company | Methods of treatment for cancer or viral infections |
| US6251870B1 (en) | 1995-04-12 | 2001-06-26 | The Procter & Gamble Company | Pharmaceutical composition for inhibiting growth of cancers |
| US5932609A (en) * | 1995-04-12 | 1999-08-03 | The Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of cancers |
| US5932604A (en) * | 1995-04-12 | 1999-08-03 | The Procter & Gamble Company | Pharmaceutical compositions for the treatment of viral infections |
| US6177460B1 (en) | 1995-04-12 | 2001-01-23 | The Procter & Gamble Company | Method of treatment for cancer or viral infections |
| US5629341A (en) * | 1995-04-12 | 1997-05-13 | The Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of viruses and cancers |
| US6686391B2 (en) | 1995-08-04 | 2004-02-03 | University Of Arizona Foundation | N-chlorophenylcarbamate and N-chlorophenylthiocarbamate compositions |
| US6242433B1 (en) | 1995-11-23 | 2001-06-05 | Laboratori Baldacci Spa | Geranylgeranyl-derivatives, process for the preparation thereof and related pharmaceutical compositions |
| WO1997019091A1 (en) * | 1995-11-23 | 1997-05-29 | Laboratori Baldacci S.P.A. | Novel geranylgeranyl-derivatives, process for the preparation thereof and related pharmaceutical compositions |
| US6194463B1 (en) * | 1997-02-25 | 2001-02-27 | Novartis Crop Protection, Inc. | N-sulphonyl and N-sulphinyl amino acid amides as microbicides |
| EP1236468A1 (en) * | 2001-02-12 | 2002-09-04 | Warner-Lambert Company | Sulfonylaminocarbonyl derivatives for the treatment of nuclear factor-kappa B mediated diseases and disorders |
| EP1281399A2 (en) * | 2001-08-01 | 2003-02-05 | Warner-Lambert Company | Dual inhibitors of wax ester and cholesteryl ester synthesis for inhibiting sebum production |
| EP1281399A3 (en) * | 2001-08-01 | 2004-02-11 | Warner-Lambert Company | Dual inhibitors of wax ester and cholesteryl ester synthesis for inhibiting sebum production |
| US20060293370A1 (en) * | 2005-06-10 | 2006-12-28 | Saunders Jeffrey O | Sulfonamide compounds and uses thereof |
| WO2006135860A1 (en) * | 2005-06-10 | 2006-12-21 | Elixir Pharmaceuticals, Inc. | Sulfonamide compounds and uses thereof |
| US20070270473A1 (en) * | 2005-06-10 | 2007-11-22 | Saunders Jeffrey O | Sulfonamide Compounds and Uses Thereof |
| US7829589B2 (en) | 2005-06-10 | 2010-11-09 | Elixir Pharmaceuticals, Inc. | Sulfonamide compounds and uses thereof |
| US20150291571A1 (en) * | 2010-11-16 | 2015-10-15 | Texas Heart Institute | Agonists that enhanced binding of integrin-expressing cells to integrin receptors |
| US10035784B2 (en) * | 2010-11-16 | 2018-07-31 | Texas Heart Institute | Agonists that enhanced binding of integrin-expressing cells to integrin receptors |
| US10071980B2 (en) | 2010-11-16 | 2018-09-11 | Texas Heart Institute | Agonists that enhanced binding of integrin-expressing cells to integrin receptors |
| US10287264B2 (en) | 2010-11-16 | 2019-05-14 | Texas Heart Institute | Agonists that enhance binding of integrin-expressing cells to integrin receptors |
Also Published As
| Publication number | Publication date |
|---|---|
| PT99436B (en) | 1999-04-30 |
| US5336690A (en) | 1994-08-09 |
| IE913875A1 (en) | 1992-05-20 |
| EP0592439A1 (en) | 1994-04-20 |
| NZ240480A (en) | 1994-08-26 |
| ES2201048T3 (en) | 2004-03-16 |
| PT99436A (en) | 1992-09-30 |
| JP3468738B2 (en) | 2003-11-17 |
| MX9101957A (en) | 1992-07-08 |
| WO1992008693A1 (en) | 1992-05-29 |
| JP3484193B2 (en) | 2004-01-06 |
| AU8950991A (en) | 1992-06-11 |
| ATE246171T1 (en) | 2003-08-15 |
| DK0592439T3 (en) | 2003-11-03 |
| CA2094807A1 (en) | 1992-05-08 |
| DE69133299T2 (en) | 2004-01-22 |
| JPH06501706A (en) | 1994-02-24 |
| JP2000319179A (en) | 2000-11-21 |
| DE69133299D1 (en) | 2003-09-04 |
| AU651155B2 (en) | 1994-07-14 |
| EP0592439B1 (en) | 2003-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5254715A (en) | Aminosulfonyl carbamates | |
| US5510379A (en) | Sulfonate ACAT inhibitors | |
| EP0556322B1 (en) | Aminosulfonyl urea acat inhibitors | |
| US5106873A (en) | ACAT inhibitors | |
| CA2094808C (en) | Oxysulfonyl urea acat inhibitors | |
| US5245068A (en) | Oxysulfonyl carbamates | |
| US5142094A (en) | Aryl substituted carbamate derivatives which are acat inhibitors | |
| EP0555351B1 (en) | Oxysulfonyl carbamates | |
| US5118697A (en) | Cyclic beta-ketoamide ACAT inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: WARNER-LAMBERT COMPANY A CORPORATION OF DE, MICHI Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:PICARD, JOSEPH A.;SLISKOVIC, DRAGO R.;REEL/FRAME:005826/0979 Effective date: 19910819 |
|
| STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
| CC | Certificate of correction | ||
| FPAY | Fee payment |
Year of fee payment: 4 |
|
| FPAY | Fee payment |
Year of fee payment: 8 |
|
| FPAY | Fee payment |
Year of fee payment: 12 |